UnitedHealth Lifts Low-End of EPS Forecast After Solid Earnings

Photo of Paul Ausick
By Paul Ausick Updated Published
This post may contain links from our sponsors and affiliates, and Flywheel Publishing may receive compensation for actions taken through them.
UnitedHealth Lifts Low-End of EPS Forecast After Solid Earnings

© Thinkstock

UnitedHealth Group Inc. (NYSE: UNH) reported second-quarter 2016 results before markets opened Tuesday. The health insurance and benefits management firm posted adjusted diluted earnings per share (EPS) of $1.96 on revenues of $46.5 billion. In the same period a year ago, UnitedHealth reported EPS of $1.73 on revenues of $36.26 billion. Second-quarter results also compare to the consensus estimates for EPS of $1.89 on revenues of $45.05 billion.

Total enrollment numbers increased year-over-year from 45.86 million to 47.98 million. Commercial enrollments rose from 29.4 million to 30.49 million. Medicare and Medicaid enrollment rose from 12.38 million to 13.44 million, and international enrollment slipped from 4.08 million to 4.05 million.

The consolidated medical care ratio rose by 0.3% to 82% for the quarter, and it included more than 50 basis points or approximately $200 million of additional full-year losses from ACA-compliant individual products above previous projections and fully absorbed within second quarter results.

The company narrowed its EPS range from a prior outlook of $7.75 to $7.95 to a new range of $7.80 to $7.95.

[nativounit]

UnitedHealth repurchased $980 million worth of its common stock in the second quarter and raised its annual dividend payment by 26% to $2.50 per share.

In the company’s UnitedHealthcare insurance business, revenues grew by $1.7 billion year over year in the quarter. Profits were down 4% year over year and operating margin fell from 6.1% to 5.2%, primarily due to the ACA-related loss.

The Optum health services business posted second-quarter revenues of $20.6 billion, up 52% year over year. Earnings from operations improved by 46%. The company attributed the increases to strong growth in pharmacy care services. Operating margin decreased by 30 basis points year over year to 6.1%.

Shares closed down about 0.4% on Monday, at $40.75 in a 52-week range of $95.00 to $142.96. The stock price was unchanged in Tuesday’s premarket session. Thomson Reuters had a consensus analyst price target of $152.05 before results were announced.

[wallst_email_signup]

Photo of Paul Ausick
About the Author Paul Ausick →

Paul Ausick has been writing for a673b.bigscoots-temp.com for more than a decade. He has written extensively on investing in the energy, defense, and technology sectors. In a previous life, he wrote technical documentation and managed a marketing communications group in Silicon Valley.

He has a bachelor's degree in English from the University of Chicago and now lives in Montana, where he fishes for trout in the summer and stays inside during the winter.

Featured Reads

Our top personal finance-related articles today. Your wallet will thank you later.

Continue Reading

Top Gaining Stocks

CBOE Vol: 1,568,143
PSKY Vol: 12,285,993
STX Vol: 7,378,346
ORCL Vol: 26,317,675
DDOG Vol: 6,247,779

Top Losing Stocks

LKQ
LKQ Vol: 4,367,433
CLX Vol: 13,260,523
SYK Vol: 4,519,455
MHK Vol: 1,859,865
AMGN Vol: 3,818,618